Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 4/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 11/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 6/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 3/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24746026 | 0.92 | MCHR1 (0.46) | CDK4CDK6CCND3MCHR1 | |
| SCHEMBL24746112 | 0.84 | MCHR1 (0.47) | CDK4CDK6MCHR1 | |
| SCHEMBL1992323 | 0.84 | CDK2 (0.43) | ACVR1CDK2CCNE1HSF1CDK4 | |
| SCHEMBL31093338 | 0.84 | CHRNB2 (0.52) | CDK2CCNE1HSF1CDK4CDK6 | |
| SCHEMBL1976516 | 0.84 | CHRNB2 (0.55) | ACVR1CDK2CCNE1HSF1CDK4 | |
| SCHEMBL12558175 | 0.84 | CHRNB2 (0.52) | CDK2CCNE1HSF1CDK4CDK6 | |
| SCHEMBL20311336 | 0.83 | ACVR1 (0.42) | ACVR1CDK2CCNE1HSF1CDK4 | |
| SCHEMBL25085564 | 0.81 | CDK4 (0.45) | CDK2CCNE1HSF1CDK4CDK6 | |
| SCHEMBL21267028 | 0.81 | CDK2 (0.41) | CDK2CCNE1HSF1CDK4CDK6 | |
| SCHEMBL22544528 | 0.81 | CDK4 (0.53) | CDK2CCNE1HSF1CDK4CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022236253-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022236256-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | NUVATION BIO INC. (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2021030623-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-08-15 | — | — | US | disclosed |
| WO-2008007123-A2 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | CDK6, CDK4, CDK9 | ACVR1 1824/4885CDK2 4/4885CCNE1 39/4885 |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | ACVR1 2422/4885CDK2 6/4885CCNE1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.